Li Watsek
Stock Analyst at Cantor Fitzgerald
(0.96)
# 1,611
Out of 4,667 analysts
76
Total ratings
29.41%
Success rate
-21.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AFMD Affimed | Reiterates: Overweight | n/a | $2.72 | - | 7 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $170 | $124.38 | +36.68% | 15 | Nov 15, 2024 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.21 | - | 5 | Nov 12, 2024 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $15.91 | - | 7 | Nov 6, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $14.62 | - | 4 | Oct 7, 2024 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $22.69 | - | 4 | Sep 9, 2024 | |
| YMAB Y-mAbs Therapeutics | Reiterates: Overweight | $20 | $10.54 | +89.75% | 2 | Sep 9, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Overweight | n/a | $20.36 | - | 5 | Sep 9, 2024 | |
| CRIS Curis | Reiterates: Overweight | n/a | $3.70 | - | 1 | May 15, 2024 | |
| VINC Vincerx Pharma | Reiterates: Overweight | n/a | $0.28 | - | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.24 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.24 | +141.94% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $4.57 | +4,714.00% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $26 | $1.14 | +2,180.70% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.22 | +125.23% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 | $0.27 | +13,814.32% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.50 | +1,420.00% | 1 | Aug 12, 2022 |
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.72
Upside: -
Ascendis Pharma
Nov 15, 2024
Reiterates: Overweight
Price Target: $170
Current: $124.38
Upside: +36.68%
ALX Oncology Holdings
Nov 12, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.21
Upside: -
Kura Oncology
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.91
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.62
Upside: -
Arvinas
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.69
Upside: -
Y-mAbs Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $10.54
Upside: +89.75%
Bicycle Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.36
Upside: -
Curis
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.70
Upside: -
Vincerx Pharma
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.28
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.24
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.24
Upside: +141.94%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $4.57
Upside: +4,714.00%
Sep 7, 2023
Reiterates: Neutral
Price Target: $26
Current: $1.14
Upside: +2,180.70%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.22
Upside: +125.23%
Sep 7, 2023
Reiterates: Overweight
Price Target: $38
Current: $0.27
Upside: +13,814.32%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.50
Upside: +1,420.00%